The Humoral Hypercalcemia of Malignancy drugs in development market research report provides comprehensive information on the therapeutics under development for Humoral Hypercalcemia of Malignancy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Humoral Hypercalcemia of Malignancy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Humoral Hypercalcemia of Malignancy and features dormant and discontinued products.
GlobalData tracks five drugs in development for Humoral Hypercalcemia of Malignancy by five companies/universities/institutes. The top development phase for Humoral Hypercalcemia of Malignancy is preclinical with two drugs in that stage. The Humoral Hypercalcemia of Malignancy pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Humoral Hypercalcemia of Malignancy pipeline products market are: CSPC Pharmaceutical Group, NeuClone and XOMA.
The key targets in the Humoral Hypercalcemia of Malignancy pipeline products market include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11), and Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor (PTH/PTHrP Type I Receptor or Parathyroid Hormone 1 Receptor or PTH1R).
The key mechanisms of action in the Humoral Hypercalcemia of Malignancy pipeline product include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) Inhibitor with four drugs in Pre-Registration. The Humoral Hypercalcemia of Malignancy pipeline products include two routes of administration with the top ROA being Subcutaneous and one key molecule types in the Humoral Hypercalcemia of Malignancy pipeline products market including Monoclonal Antibody.
Humoral Hypercalcemia of Malignancy overview
Humoral hypercalcemia of malignancy (HHM) is caused by too much parathyroid hormone-related peptide (PTHrP) from malignant tumors. Primary hyperparathyroidism, PTH production by malignant cells, local osteolytic hypercalcemia, ectopic hyperparathyroidism, and vitamin D-secreting lymphomas can cause HHM. Symptoms include anxiety, depression, cognitive dysfunction, lethargy, weakness, fatigue, hyporeflexia, confusion, stupor, and in the most severe cases, coma. PTH and vitamin D levels, kidney function, and calcium levels in urine help in its diagnosis. HHM can be treated with zoledronic acid, ibadronate, pamidronate, and etidronate.
For a complete picture of Humoral Hypercalcemia of Malignancy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
